BIODESIX, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
BIODESIX, INC. (BDSX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $2.18 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2024-03-01
- BIODESIX, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-12-31 was $328.00K, a 56.15% decline year-over-year.
- BIODESIX, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-09-30 was $457.00K, a 40.73% decline year-over-year.
- BIODESIX, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-06-30 was $634.00K, a 41.52% increase year-over-year.
- BIODESIX, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-03-31 was $760.00K, a 171.43% increase year-over-year.
- BIODESIX, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $2.18M, a 3.03% decline from fiscal 2022.
- BIODESIX, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $2.25M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2023-12-31 | $328.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $785.00K derived: sum of 2 quarters · filed 2024-03-01 | $1.42M derived: sum of 3 quarters · filed 2024-03-01 | $2.18M 10-K · filed 2024-03-01 |
| 2023-09-30 | $457.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.09M derived: sum of 2 quarters · filed 2023-11-07 | $1.85M 10-Q · filed 2023-11-07 | $2.60M derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-06-30 | $634.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.39M 10-Q · filed 2023-08-07 | $2.14M derived: sum of 3 quarters · filed 2024-03-01 | $2.91M derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-03-31 | $760.00K 10-Q · filed 2023-05-11 | $1.51M derived: sum of 2 quarters · filed 2024-03-01 | $2.28M derived: sum of 3 quarters · filed 2024-03-01 | $2.73M derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-12-31 | $748.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $1.52M derived: sum of 2 quarters · filed 2024-03-01 | $1.97M derived: sum of 3 quarters · filed 2024-03-01 | $2.25M 10-K · filed 2024-03-01 |
| 2022-09-30 | $771.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.22M derived: sum of 2 quarters · filed 2023-11-07 | $1.50M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $448.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $728.00K 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $280.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |